Literature DB >> 20636354

Penetration enhancement of two topical 5-aminolaevulinic acid formulations for photodynamic therapy by erbium:YAG laser ablation of the stratum corneum: continuous versus fractional ablation.

Bernadette Forster1, Annette Klein, Rolf-Markus Szeimies, Tim Maisch.   

Abstract

5-Aminolaevulinic acid (ALA) is used in photodynamic therapy (PDT). Response rates of PDT vary widely, which may be because of the limited uptake of topically applied photosensitisers. We investigated skin penetration and fluorescence induction of protoporphyrin IX (PpIX) after applying either 20% ALA cream or 20% aminolaevulinic acid solution on laser-stripped stratum corneum (SC) in an ex vivo full-thickness porcine skin model. Both formulations are used in clinical practice. To enhance the skin penetration of ALA, we used two different 2940-nm erbium:yttrium-aluminium-garnet (Er:YAG) laser systems to partially ablate the SC: continuous and fractional ablation. Different fluences were applied ranging from 0.5 to 1.5 J/cm(2) (continuous ablation) and from 4 to 24 J/cm(2) (fractional ablation). Fluorescence microscopy was used for detecting PpIX-induced fluorescence. Compared to skin without laser pretreatment, mean fluorescence intensity (MFI) of PpIX was enhanced 13.8-fold after continuous ablation with 1.0 J/cm(2) and 7.3-fold after fractional ablation with 4 J/cm(2); each laser procedure was followed by 4-h incubation with lipophilic ALA cream. Optimal parameters for continuous ablation without damage to the epidermis were 1 J/cm(2) for both formulations, fractional ablation was best with 4 J/cm(2). Histological evaluations of laser-treated skin showed necrosis and apoptosis, depending on light dose. In laser-stripped skin, PpIX fluorescence was detected earlier and reached deeper epidermal layers than in untreated skin. Continuous laser ablation induced higher PpIX fluorescence levels than fractional ablation. This method offers a promising new tool for enhancing ALA penetration in PDT without damaging the underlying tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636354     DOI: 10.1111/j.1600-0625.2010.01093.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  16 in total

Review 1.  [New developments in laser therapy].

Authors:  P Babilas; M Landthaler
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

2.  Photodynamic therapy with ablative carbon dioxide fractional laser for treating Bowen disease.

Authors:  Sue Kyung Kim; Ji-Youn Park; Hyo Sang Song; You-Sun Kim; You Chan Kim
Journal:  Ann Dermatol       Date:  2013-08-13       Impact factor: 1.444

3.  Is the Fractional Laser Still Effective in Assisting Cutaneous Macromolecule Delivery in Barrier-Deficient Skin? Psoriasis and Atopic Dermatitis as the Disease Models.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Calvin T Sung; Pei-Ying Liu; Jia-You Fang
Journal:  Pharm Res       Date:  2018-04-26       Impact factor: 4.200

Review 4.  [Photodynamic therapy-trends and new developments].

Authors:  R-M Szeimies; S Karrer
Journal:  Hautarzt       Date:  2020-12-10       Impact factor: 0.751

5.  Utilizing non-ablative fractional photothermolysis prior to ALA-photodynamic therapy in the treatment of acne vulgaris: a case series.

Authors:  Sarah Qureshi; Jennifer Y Lin
Journal:  Lasers Med Sci       Date:  2016-10-14       Impact factor: 3.161

6.  Vehicle type affects filling of fractional laser-ablated channels imaged by optical coherence tomography.

Authors:  Uffe Høgh Olesen; Mette Mogensen; Merete Haedersdal
Journal:  Lasers Med Sci       Date:  2017-02-17       Impact factor: 3.161

7.  Transdermal delivery of three vitamin C derivatives by Er:YAG and carbon dioxide laser pretreatment.

Authors:  Chun-Hsun Huang; Hsin-Ching Sung; Chien-Yu Hsiao; Sindy Hu; Yu-Shien Ko
Journal:  Lasers Med Sci       Date:  2012-07-24       Impact factor: 3.161

8.  Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy.

Authors:  Connor Thunshelle; Rui Yin; Qiquan Chen; Michael R Hamblin
Journal:  Curr Dermatol Rep       Date:  2016-07-13

Review 9.  Physical energy for drug delivery; poration, concentration and activation.

Authors:  Shanmugamurthy Lakshmanan; Gaurav K Gupta; Pinar Avci; Rakkiyappan Chandran; Magesh Sadasivam; Ana Elisa Serafim Jorge; Michael R Hamblin
Journal:  Adv Drug Deliv Rev       Date:  2013-06-07       Impact factor: 15.470

10.  Transcutaneous vaccination via laser microporation.

Authors:  Richard Weiss; Michael Hessenberger; Sophie Kitzmüller; Doris Bach; Esther E Weinberger; Wolf D Krautgartner; Cornelia Hauser-Kronberger; Bernard Malissen; Christof Boehler; Yogeshvar N Kalia; Josef Thalhamer; Sandra Scheiblhofer
Journal:  J Control Release       Date:  2012-06-29       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.